Abstract 2351P
Background
Cancer in adolescents and young adults (AYAs, aged 18-39 years at first cancer diagnosis) is nowadays considered as a separate entity with specific care needs. However, once the diagnosis has been established, AYA patients are mostly treated as having cancer at an older age. Breakthroughs in treatment options are scarce and AYA patients are underrepresented in clinical trials. To improve healthcare outcomes, there is a large unmet need for obtaining more knowledge and better (genomic) understanding of cancers at AYA age.
Methods
As an independent not-for-profit cancer diagnostics organization and data provider, Hartwig Medical Foundation performs clinical-grade whole genome sequencing (WGS) for cancer patients using a single small fresh-frozen biopsy and a matching blood sample. In addition to comprehensive diagnostic reporting of oncology-related genomics aberrations (including mutations, copy-number alterations, fusions and mutational signatures like MSI, TMB, HRD) all WGS data is (following patient consent) stored in the Hartwig Database. This data (>5500 patients) is available to the academic community to facilitate research and improve future cancer patient care.
Results
The Hartwig Database currently includes WGS and associated clinical data for 192 metastatic AYA cancer patients. Although a fair number in total, the numbers per tumor indication are quite small with n > 30 for only three indications (breast n=49, bone/soft tissue n=33 and GI-tract n=34). Also, the distribution does not follow the AYA cancer type prevalence as registered in the Dutch national cancer registry, with e.g. GI-tract (18% vs 9%) and bone/soft tissue (17% vs 2%) overrepresented and male/female reproductive organs underrepresented (8 vs 18%). Preliminary analysis of the frequency of driver alterations of some of the well-known oncogenes (e.g. PIK3CA, BRAF, KRAS, ERBB2) do not reveal differences between AYA and non-AYA cancers although the low number of AYA samples hamper conclusiveness.
Conclusions
To better facilitate research for AYA patients and to offer all possible treatment options (e.g. clinical trials), more patients will need to be analyzed by WGS. For this purpose, a dedicated project has been initiated that includes tumor-normal WGS of 1000 AYA patients in the next 3 years.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2346P - Spatial and quantified molecular characterization of high endothelial venule predictive of immunotherapy response
Presenter: Kunheng Du
Session: Poster session 16
2347P - Correlation between second primary cancers and first primary cancers: A systematic review and meta-analysis of 9 million cancer patients
Presenter: Xinyu Wang
Session: Poster session 16
2348P - High-throughput screening reveals GSK1838705A as a potent inhibitor of CAFs-promoted tumor progression in esophageal squamous cell carcinoma
Presenter: hongfang zhang
Session: Poster session 16
2349P - Patterns and frequency of pathogenic germline variants (PGVs) among non-western young male patients with cancer: The Jordanian exploratory cancer genetics (Jo-ECAG) study
Presenter: Hira Bani Hani
Session: Poster session 16
2350P - Single-cell RNA-seq dissecting the initiating liver metastasis cells in various cancers
Presenter: Shu-yue Zheng
Session: Poster session 16
2352P - Sex-based differences in genomic alterations and biomarkers in anal squamous cell carcinoma (ASCC)
Presenter: Stefano Cereda
Session: Poster session 16
2353P - Anti-cancer effects of HDAC8 specific inhibitors EC-352H and EC-374H in lymphoma
Presenter: So Young Lee
Session: Poster session 16
2354P - Computational pathology-derived features capture varied epithelial-mesenchymal transition (EMT) states
Presenter: Herbert Levine
Session: Poster session 16
2355P - Carcinoembryonic antigen (CEA) expression in human tumors: A tissue microarray study on 15,413 tumors
Presenter: Kristina Jansen
Session: Poster session 16
2356P - The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC
Presenter: Arianna Marinello
Session: Poster session 16